/Cooper%20Companies%2C%20Inc_%20phone%20and%20site-by%20T_Schneider%20via%20Shutterstock.jpg)
San Ramon, California-based The Cooper Companies, Inc. (COO) is a global medical device company that develops, manufactures, and markets contact lenses. With a market cap of around $14 billion, the company operates in two segments, CooperVision and CooperSurgical.
Companies worth $10 billion or more are generally described as “large-cap” stocks, and Cooper Companies fits this criterion perfectly. The company specializes in contact lenses and eye care products, and also offers a wide range of medical devices and fertility solutions for women’s health. It focuses on innovation, patient outcomes, and global expansion to drive long-term growth across healthcare markets.
Shares of Cooper Companies have declined 37.9% from its 52-week high of $112.38. COO stock has dropped 12.8% over the past three months, a steeper decline than the First Trust Indxx Global Medical Devices ETF’s (MDEV) 2.3% decrease.
Longer term, shares of COO have plunged 24.1% on a YTD basis, notably underperforming MDEV’s nearly 2.7% downtick over the same time frame. Moreover, Cooper’s stock has fallen 23.8% over the past 52 weeks, compared to MDEV’s marginal dip.
Despite some fluctuations, the stock has been trading below its 50-day moving average since late October last year and its 200-day moving average since early December last year.
Despite posting strong Q2 2025 results on May 29, shares of COO tumbled 14.6% the next day. Quarterly revenue rose 6.3% year-over-year to $1 billion, exceeding Street expectations, while adjusted EPS increased 19.6% year-over-year to $0.96, also beating estimates. However, the stock declined as the company lowered its full-year organic growth outlook to 5% to 6%, down from the previous forecast of 6% to 8%, which dampened investor sentiment.
Compared to its rival, Align Technology, Inc. (ALGN) has slightly underperformed the COO stock over the past 52 weeks, decreasing 25.7%. However, shares of ALGN have declined 13.7% YTD, a less pronounced dip compared to COO stock.
Although COO has underperformed, analysts are moderately optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from the 16 analysts covering the stock. As of writing, the stock is trading below the mean price target of $94.87.
